Abivax S.A.

ABVXNASDAQHealthcare● Active

$101.53

+$0.00(+0.00%)

Market Cap$6.7B

P/E Ratio—

52W High$148.83

52W Low$5.69

Avg Volume1.4M

Open$101.70

Beta-0.20

Free Cash Flow Financials Revenue

Abivax S.A. (ABVX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ABVX · free cash flow · updated Jun 8, 2026

Core FCF metrics

ABVX · FCF · TTM · margin & CAGR

Free cash flow was −$155.8M for FY2025 (fiscal year ending 2025-12-31), down 0.7% year-over-year

FY2025 Free Cash Flow−$155.8M▼ -0.7% YoY

Trailing 12M (TTM)−$250.0Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ABVX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$155.7M(0M)−$155.8M▼ 0.7%—

FY2024−$154.1M(1M)−$154.7M▼ 54.3%—

FY2023−$100.0M(0M)−$100.3M▼ 84.8%—

FY2022−$53.9M(0M)−$54.3M▼ 14.7%—

FY2021−$45.7M(2M)−$47.3M▼ 54.0%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ABVX · P/FCF · FCF yield · FCF per share

Abivax S.A. (ABVX) reported negative free cash flow of −$0.16B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ABVX · cash flow statement · operating / investing / financing

For FY2025, Abivax S.A. generated −$155.7M in operating cash flow and spent 0M in capital expenditures, yielding −$155.8M in free cash flow.

Operating Activities

−$155.7M

Cash from core business operations

2025-12-31

Investing Activities

−$13.2M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$531.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$155.7M) − |CapEx| (0M) = FCF (−$155.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ABVX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Abivax S.A.YOU

ABVX

−$155.8M-0.7%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Abivax S.A. (ABVX) reported free cash flow of −$155.8M for FY2025 (fiscal year ending 2025-12-31), down 0.7% year-over-year.

Abivax S.A. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 12 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ABVX free cash flow · 8 questions

Abivax S.A. free cash flow was −$155.8M for FY2025, down 0.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$250.0M.

ABVX free cash flowABVX FCFABVX FCF 2025ABVX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Abivax S.A. · Abivax S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026